Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 18/20 | 0.54 |
| ▸ | GBA1 | P04062 | 6/20 | 0.50 |
| ▸ | UGCG | Q16739 | 5/20 | 0.48 |
| ▸ | MGAM | O43451 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SI | P14410 | 2/20 | 0.48 |
| ▸ | AGL | P35573 | 2/20 | 0.48 |
| ▸ | LCT | P09848 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668757 | 0.81 | GBA2 (0.57) | GBA2GBA1UGCGMGAMGAA | |
| SCHEMBL13672852 | 0.80 | GBA2 (0.52) | GBA2GBA1UGCGMGAMGAA | |
| SCHEMBL13668744 | 0.79 | GBA2 (0.51) | GBA2GBA1UGCGMGAMGAA | |
| SCHEMBL24586992 | 0.77 | ALDH1A1 (0.44) | GBA2GBA1 | |
| SCHEMBL24587719 | 0.77 | ALDH1A1 (0.44) | GBA2GBA1 | |
| SCHEMBL13668762 | 0.76 | GBA2 (0.52) | GBA2GBA1UGCGMGAMGAA | |
| SCHEMBL16451614 | 0.76 | GBA2 (0.48) | GBA2GBA1UGCGMGAMGAA | |
| SCHEMBL4419614 | 0.75 | GBA2 (0.48) | GBA2GBA1UGCGMGAMGAA | |
| SCHEMBL14601217 | 0.75 | GBA2 (0.51) | GBA2GBA1UGCGMGAMGAA | |
| SCHEMBL24587010 | 0.75 | ALDH1A1 (0.45) | GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680403-B1 | DEOXYNOJIRIMYCIN ANALOGUES AND THEIR USES AS GLUCOSYLCERAMIDASE INHIBITORS | GENZYME CORP (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-1680403-B1 | DEOXYNOJIRIMYCIN ANALOGUES AND THEIR USES AS GLUCOSYLCERAMIDASE INHIBITORS | GENZYME CORP (US) | 2016-06-29 | — | — | EP | disclosed |
| US-7528153-B2 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | GENZYME CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070066581-A1 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | GENZYME CORPORATION | 2007-03-22 | — | — | US | disclosed |
| EP-1528056-A1 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | Academisch Ziekenhuis bij de Universiteit van Amsterdam (NL) | 2005-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066581-A1 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | GAA, GBA1, GBA3 | GBA2 9/4885GBA1 2/4885UGCG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.